Citius Pharmaceuticals (CTXR) AI Stock Analysis

• Market Cap: $18.69M
• Dividend Yield: N/A
• Average Volume (3M): 1.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.29
• Revenue Growth: N/A
• EPS Growth: 18.73%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 20,762,917
• 10 Day Avg. Volume: 511,305
• 30 Day Avg. Volume: 1,160,981
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 85.26
• Enterprise Value/Gross Profit: -64.56
• Enterprise Value/Ebitda: -0.33
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $0.82 ▼(-54.81% Downside)

The score is held back primarily by weak financial performance (no revenue, continued losses and cash burn, and declining equity). Technicals also lean bearish with price below major moving averages and negative MACD. Offsetting these, recent corporate events are positive given LYMPHIR’s launch and commercialization progress, while valuation signals are largely inconclusive due to negative earnings and no dividend data.

Positive Factors

Strategic Partnerships

Strategic partnerships enhance product development and market reach, providing a pathway for revenue growth and innovation in the long term.

Innovative Product Pipeline

A diverse and innovative product pipeline positions the company to address unmet medical needs, potentially leading to future market leadership and revenue streams.

Asset Stability

A strong asset base provides financial stability, enabling the company to withstand industry volatility and invest in long-term growth opportunities.

Negative Factors

Cash Burn Issues

Persistent cash burn can strain financial resources, requiring ongoing external financing and potentially diluting shareholder value over time.

Operational Inefficiencies

Operational inefficiencies hinder profitability and cash generation, challenging the company's ability to achieve sustainable financial performance.

Dependence on External Financing

Dependence on external financing can lead to shareholder dilution and reflects challenges in achieving self-sustaining financial operations.

Citius Pharmaceuticals Business Overview & Revenue Model

Company Description

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

How the Company Makes Money

Citius Pharmaceuticals generates revenue through the development and commercialization of its pipeline of proprietary and collaborative pharmaceutical products. Key revenue streams include sales from FDA-approved products, licensing agreements, and strategic partnerships with other pharmaceutical companies. Citius focuses on advancing its clinical-stage products to commercialization, where it can earn revenues from product sales and royalties. Significant partnerships with healthcare organizations and research institutions also contribute to its earnings by facilitating product development and expanding market reach. Additionally, the company may receive milestone payments based on achieving specific regulatory or commercial objectives.

Citius Pharmaceuticals Financial Statement Overview

Summary

Overall financial profile is weak due to being pre-revenue with persistent, sizable net losses and ongoing negative operating/free cash flow (continued cash burn). The main offset is very low leverage (debt-to-equity near zero), but equity has declined materially over time, indicating continued funding needs and balance-sheet erosion.

Income Statement

The company remains pre-revenue (total revenue is $0 across all reported years), so profitability is entirely dependent on expense control rather than commercial execution. Losses are persistent and large, with net income roughly $23.1M (2021) worsening to about $39.7M (2025), indicating rising operating spend and limited operating leverage. A modest positive is that losses have not grown in a straight line every year, but the overall trajectory still points to ongoing, material earnings pressure until revenue arrives.

Balance Sheet

Leverage is very low, with debt-to-equity consistently near zero (about 0.4%–1.2% recently), which reduces solvency risk and provides flexibility. However, equity has trended down meaningfully over time (from about $132.2M in 2021 to $67.6M in 2025), reflecting continued losses and potential ongoing dilution/financing needs. Returns on equity are deeply negative (roughly -17% to -59% across the period), underscoring that capital is being consumed rather than compounded.

Cash Flow

Cash generation is weak: operating cash flow is consistently negative (roughly -$16.9M in 2020 to -$26.6M in 2025), and free cash flow is also negative in every year shown, implying ongoing cash burn to fund operations. A positive is that free cash flow burn improved in 2025 versus 2024 (free cash flow growth of ~29%), but the business is still far from self-funding. Overall, the cash flow profile suggests continued reliance on external capital until commercialization or a major cost reset.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	155.93K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-205.90K	0.00	-209.61K	-194.32K	-179.68K	-164.87K
EBITDA	-40.90M	0.00	-38.64M	-31.77M	-32.88M	-22.88M
Net Income	-40.26M	-39.74M	-39.14M	-32.54M	-33.64M	-23.13M
Balance Sheet
Total Assets	127.68M	130.94M	116.65M	103.61M	114.00M	142.43M
Cash, Cash Equivalents and Short-Term Investments	6.09M	4.25M	3.25M	26.48M	41.71M	70.07M
Total Debt	1.88M	813.27K	262.87K	481.25K	678.23K	855.47K
Total Liabilities	60.12M	53.41M	42.55M	12.18M	10.57M	9.65M
Stockholders Equity	65.06M	67.55M	70.08M	90.83M	102.83M	132.18M
Cash Flow
Free Cash Flow	-20.58M	-26.55M	-28.20M	-29.06M	-28.36M	-64.26M
Operating Cash Flow	-20.58M	-26.55M	-28.20M	-29.06M	-28.36M	-24.25M
Investing Cash Flow	-5.00M	-5.75M	-5.00M	0.00	0.00	-40.01M
Financing Cash Flow	13.76M	33.30M	9.97M	13.83M	0.00	120.47M

Citius Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Negative. The current price of 1.81 is above the 20-day moving average (MA) of 0.97, above the 50-day MA of 1.14, and above the 200-day MA of 1.19, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 42.80 is Neutral, neither overbought nor oversold. The STOCH value of 59.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTXR.

Citius Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PASG	50 Neutral	$57.20M	-1.27	-87.18%	―	―	38.42%
MRKR	49 Neutral	$34.51M	-1.68	-110.67%	―	-12.99%	-13.67%
CTXR	48 Neutral	$18.69M	-0.24	-54.40%	―	―	18.73%
SYBX	43 Neutral	$14.27M	-4.60	-27.54%	―	-100.00%	93.62%

Citius Pharmaceuticals Corporate Events

Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma

On December 1, 2025, Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, announced the commercial launch of LYMPHIR™, a novel IL-2 receptor-directed fusion protein. This product, approved by the FDA, is designed for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy. The launch marks a significant milestone for Citius Oncology as LYMPHIR is their first marketed product, potentially impacting the company’s market position and providing growth opportunities in the estimated $400 million U.S. market for this condition.

The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Citius Pharmaceuticals Announces LYMPHIR Commercialization Plans

On October 23, 2025, Citius Pharmaceuticals announced the upcoming commercialization of LYMPHIR, a treatment for cutaneous T-cell lymphoma, planned for Q4 2025. This follows its FDA approval in August 2024 and is expected to impact the U.S. market significantly, with an estimated addressable market of over $400 million. The company has invested heavily in pre-commercial activities, including securing distribution agreements and developing a marketing strategy, positioning itself strongly in the oncology market.

The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Citius Pharmaceuticals Secures $6M in Stock Offering

On October 20, 2025, Citius Pharmaceuticals entered into a securities purchase agreement with an institutional investor for a registered direct offering of common stock and pre-funded warrants, closing on October 21, 2025. The offering raised approximately $6 million in gross proceeds, with net proceeds intended to support the commercial launch of LYMPHIR, development initiatives, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent, receiving a cash fee and warrants as compensation. The offering aligns with Citius’s strategy to enhance its market position and fund its pipeline advancements.

The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.